Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-K stay in one workspace.
INO
$1.16
+0.43%
INO
· Inovio Pharmaceuticals, Inc.
$1.16
+0.01 (+0.43%)
At close · Oct 8
View the 10-K filed Mar 12, 2026
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Customer concentration
— key customers 100% of revenue
Key customers — 100% of revenue (the years ended December 31, 2025 and 2024)
“During the years ended December 31, 2025 and 2024, we derived 100% of our revenue from ApolloBio.”
Market Cap
$119.42M
Shares
103.40M
Volume · Oct 7
2.8M
Avg daily vol (3M)
3.79M
All webcasts
Earnings call · FY2019 Q4
Inovio Pharmaceuticals, Inc. (INO) Q4 2019 Earnings Call
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Revenue
$279,488
-88.8% YoY
Diluted EPS
-$4.56
Net income
-$37.66M
Research materials
Open the source you need; every reader stays inside this workspace.
Quarter detail
How the reported period landed and where the business moved.
SEC filing · Item 2.02
8-K earnings release
Filed Mar 9, 2020 · complete as-filed document
SEC periodic report
10-K report
Filed Mar 12, 2020 · complete as-filed document